The civic record
Read. Follow. Verify.House Bill 1643 Allows Therapeutic Psilocybin Use and Updates Investigational Drug Access Rules
Last action · February 26, 2026: HCS Reported Do Pass (H)Sponsor: Matthew Overcast
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
House Bill 1643 permits adults aged 21 and older with qualifying conditions to acquire, use, and possess psilocybin for therapeutic purposes when registered with the Department of Mental Health alongside a qualified facilitator and a physician's documentation. The measure also modifies state laws regarding experimental treatments, removing an exclusion on Schedule I controlled substances for certain clinical trials and requiring the Department of Health and Senior Services to create a registry of manufacturers.
Qualifying patients gain legal access to specific therapeutic substances without state or local civil penalties, while licensed health care providers and state-registered laboratories receive explicit liability protections when participating in approved treatment protocols.
- House Bill 1643 was introduced during the 2026 Regular Session of the Missouri General Assembly by Representative Matthew Overcast. context
- State legislative efforts regarding alternative therapies frequently evaluate the clinical trial status of controlled substances supervised by the United States Food and Drug Administration. context
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Patients with qualifying conditions
Adults with terminal illnesses or specified mental health disorders gain legal access to therapeutic psilocybin and investigational drugs without civil or criminal penalties.
Physicians and certified nurse practitioners
Providers can supply medical documentation and recommendations for eligible patients and investigational treatments without facing state regulatory discipline or professional license revocation.
Psilocybin facilitators
Licensed medical and mental health professionals who complete specialized training programs can legally assist patients during psilocybin sessions.
Manufacturers of investigational drugs
Makers of investigational treatments are permitted to provide products to eligible patients either freely or with cost recovery, and those utilizing controlled substances must register with the state.
Key Facts
- Adults aged twenty-one or older suffering from end-of-life conditions, posttraumatic stress disorder, major depressive disorder, or substance use disorders may possess and use psilocybin therapeutically without state or local penalty.
- Patients must provide the Department of Mental Health with documentation from a physician or certified nurse practitioner, the name of a licensed facilitator, the treatment location address, and a time period not exceeding twelve months.
- Psilocybin intended for ingestion must be tested by a state-licensed laboratory, and total use is capped at no more than 150 milligrams of psilocybin analyte per twelve-month period.
- Facilitators must complete a training program specific to psilocybin approved for continuing education credit by the American Psychological Association consisting of at least thirty hours of synchronous learning.
Show all 8 facts
- The Department of Mental Health must maintain the confidentiality of personally identifiable protected information collected under the psilocybin provisions and is prohibited from disclosing it to the federal government.
- Manufacturers of investigational drugs, biological products, or devices must register with the Department of Health and Senior Services, which must create a registry for those involving controlled substances before November 1, 2026.
- State agencies and regulatory boards are prohibited from revoking or failing to renew a physician's license solely based on a recommendation or prescription for an investigational drug or documentation for therapeutic psilocybin use.
- Health care insurers and the Department of Corrections are not required to provide coverage for the cost of any investigational drug, biological product, or device.
Frequently Asked Questions
Who is eligible to use psilocybin therapeutically under this bill?
Does insurance have to pay for investigational drugs or psilocybin treatments?
What training must a psilocybin facilitator complete?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
8 actions- Feb 26, 2026HouseCommitteeHCS Reported Do Pass (H)
- Feb 25, 2026HouseCommitteeHCS Voted Do Pass (H)
- Feb 25, 2026HouseExecutive Session Completed (H)
- Feb 16, 2026HousePublic Hearing Completed (H)
- Feb 12, 2026HouseCommitteeReferred: Emerging Issues(H)
- Jan 8, 2026HouseFloorRead Second Time (H)
Show 2 earlier actions
- Jan 7, 2026HouseIntroducedRead First Time (H)
- Dec 1, 2025HouseIntroducedPrefiled (H)
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Exclusion of Schedule I Substances Lifted for Specific Trials
The bill removes previous language excluding Schedule I controlled substances from investigational treatment pathways, explicitly integrating therapeutic psilocybin under strict medical supervision.
Connected Entities
Sources
house.mo.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy80Intensity of disagreement among stakeholders
- Entertainment15Compellingness for a non-policy-wonk reader
- Buzz75Current news / social attention level
Publisher tools